Simultaneous determination of maraviroc and raltegravir in human plasma by HPLC-UV

IUBMB Life

Volumn 61, Issue 4, 2009, Pages 470-475

  Notari, Stefania ^a   Tommasi, Chiara ^a   Nicastri, Emanuele ^a   Bellagamba, Rita ^a   Tempestilli, Massimo ^a   Pucillo, Leopoldo Paolo ^a   Narciso, Pasquale ^a   Ascenzi, Paolo ^a,b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b ROMA TRE UNIVERSITY   (Italy)

Author keywords

Anti HIV drugs; HPLC UV; Maraviroc; Raltegravir; Therapeutic drug monitoring

Indexed keywords

1 VINYL 2 PYRROLIDINONE; DIVINYLBENZENE; MARAVIROC; RALTEGRAVIR; 2 PYRROLIDONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOHEXANE DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; BLOOD SAMPLING; DRUG BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SOLID PHASE EXTRACTION; ULTRAVIOLET SPECTROSCOPY; BLOOD; DRUG MONITORING; METHODOLOGY; ULTRAVIOLET RADIATION;

ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANES; DRUG MONITORING; HUMANS; PYRROLIDINONES; TRIAZOLES; ULTRAVIOLET RAYS;

EID: 67650373281     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.181     Document Type: Article

References (16)

1. Back, D., Gatti, G., Fletcher, C., Garaffo, R., Haubrich, R., Hoetelmans, R., Kurowski, M., Luber, A., Merry, C., and Perno, C. F. (2002) Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 16 (Suppl 1), S5-S37.
2. Aarnoutse, R. E., Schapiro, J. M., Boucher, C. A., Hekster, Y. A., and Burger, D. M. (2003) Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 63, 741-753.
3. Fletcher, C. V. (2003) Enfuvirtide, a new drug for HIV infection. Lancet 361, 1577-1578.
4. Rakhmanina, N. Y., van den Anker, J. N., and Soldin, S. J. (2004) Therapeutic drug monitoring of antiretroviral therapy. AIDS Patient Care STDS 18, 7-14.
5. Boffito, M., Acosta, E., Burger, D., Fletcher, C. V., Flexner, C., Garaffo, R., Gatti, G., Kurowski, M., Perno, C. F., Peytavin, G., Regazzi, M., and Back, D. (2005) Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy. Antivir. Ther. 10, 375-392.
6. Wertheimer, B. Z., Freedberg, K. A., Walensky, R. P., Yazdanapah, Y., and Losina, E. (2006) Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin. Trials 7, 59-69.
7. Back, D., Gibbons, S., and Khoo, S. (2006) An update on therapeutic drug monitoring for antiretroviral drugs. Ther. Drug Monit. 28, 468-473.
8. Nettles, R. E., Kieffer, T. L., Parsons, T., Johnson, J., Cofrancesco, J. Jr, Gallant, J. E., Carson, K. A., Siliciano, R. F., and Flexner, C. (2006) Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin. Infect. Dis. 42, 1189-1196.
9. Ivanovic, J., Nicastri, E., Ascenzi, P., Bellagamba, R., De Marinis, E., Notari, S., Pucillo L. P., Tozzi, V., Ippolito, G., and Narciso, P. (2008) Therapeutic drug monitoring in the management of HIV-infected patients. Curr. Med. Chem. 15, 1925-1939.
10. Hughes, A., Barber, T., and Nelson, M. (2008) New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J. Infect. 57, 1-10.
11. Wood, A. and Armour, D. (2005) The discovery of the CCR5 receptor antagonist, UK-427 857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem. 43, 239-271.
12. Ndegwa, S. (2007) Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1. Issues Emerg. Health Technol. 110, 1-8.
13. Evering, T. H. and Markowitz, M. (2008) Raltegravir: an integrase inhibitor for HI V-1. Exp. Opin. Invest. Drugs 17, 413-422.
14. Steigbigel, R. T., Cooper, D. A., Kumar, P. N., Eron, J. E., Schechter, M., Markowitz, M., Loutfy, M. R., Lennox, J. L., Gatell, J. M., Rockstroh, J. K., Katlama, C., Yeni, P., Lazzarin, A., Clotet, B., Zhao, J., Chen, J., Ryan, D. M., Rhodes, R. R., Killar, J. A., Gilde, L. R., Strohmaier, K. M., Meibohm, A. R., Miller, M. D., Hazuda, D. J., Nessly, M. L., DiNubile, M. J., Isaacs, R. D., Nguyen, B. Y., and Teppler, H. (2008) Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359, 339-354.
15. D'Avolio, A., Baietto, L., Siccardi, M., Sciandra, M., Simiele, M., Oddone, V., Bonora, S., and Di Perri, G. (2008) An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther. Drug Monit. 30, 662-669.
16. Rezk, N. L., White, N., and Kashuba, A. D. (2008) An accurate and precise high-performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction. Anal. Chim. Acta 628, 204-213.